IVERIC bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Glenn P. Sblendorio
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 Sylvan Way Parsippany NJ United States of America 07054
- IPO Date
- Sep 25, 2013
- CIK
- 0001410939
- Website
- ivericbio.com
- Similar Companies
- Business
- IVERIC bio, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of treatments for retinal diseases with significant unmet medical needs. The company's core products include its lead clinical-stage product candidate, avacincaptad pegol (also known as Zimura or ACP), a complement C5 inhibitor developed for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In addition, IVERIC bio develops gene therapy programs using adeno-associated virus (AAV) vectors targeting orphan inherited retinal diseases such as rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and BEST1-related retinal diseases. The company conducts research and development activities focused on ophthalmology and retinal diseases and advances a pipeline that includes other novel candidates, such as an HtrA1 inhibitor for GA currently under preclinical development. IVERIC bio manages partnerships for manufacturing and development, notably its strategic manufacturing relationship with Catalent Biologics for GMP-grade AAV vector production supporting its gene therapy candidates. Recent major changes include IVERIC bio's acquisition by Astellas Pharma Inc. completed in July 2023, making IVERIC bio a wholly owned subsidiary of Astellas. This acquisition supports Astellas’ expansion in the ophthalmology field and complements its corporate strategic growth plans. In 2023, the U.S. FDA granted approval for IVERIC bio's IZERVAY™ (avacincaptad pegol intravitreal solution), marking a significant milestone as a treatment option for GA secondary to AMD and advancing the company’s commercial launch preparations. The FDA also accepted the company's New Drug Application (NDA) and granted priority review for avacincaptad pegol, reflecting strong clinical data from Phase 3 trials (GATHER1 and GATHER2) demonstrating the product’s efficacy in reducing geographic atrophy progression. IVERIC bio operates primarily from its headquarters in Parsippany, New Jersey, and targets global markets with a focus on ophthalmic and retinal disease patients. The company leverages its gene therapy platform and complement inhibition technology to address conditions that lead to irreversible vision loss. Since its founding, IVERIC bio has evolved into a specialized ophthalmology-focused biopharmaceutical enterprise with a robust clinical pipeline and strong backing from Astellas Pharma.
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
Astellas Completes Acquisition of Iveric Bio
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
Iveric Bio stock surges on Astellas Pharma takeover deal
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
These Are the Top 10 Holdings of David Kim
Why Is Iveric Bio (ISEE) Stock Up 25% Today?
IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
Iveric Bio to Present at Upcoming Investor Conferences
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results
These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study